Skip to content
The Quiet LedgerBeyond the noise. On the record.
hr 5850 · 118th Congress · House

To nullify modifications made by the Food and Drug Administration on January 3, 2023, to the risk evaluation and mitigation strategy under section 505-1 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355-1) for mifepristone, and for other purposes.

—Sign in to watch / set alerts
TQL analysis
Not yet gradedThis bill has no published Quiet Ledger grade yet.
Legislative structure
Cosponsors
1 current · 1 total
Actions
3
Roll calls
0
Criterion breakdown8 criteria · max 90
No grade to break down.
Actions (3)
DateTimeAction
2023-09-29—Referred to the House Committee on Energy and Commerce.
2023-09-29—Introduced in House
2023-09-29—Introduced in House

The Quiet Ledger grades legislation on its content. A bill grade is analysis of the bill — not a grade of its sponsor or of any member who voted on it.